Molecular remission after allogeneic or autologou8 transplantation of hematopoietic stem cells for multiple myeloma

Giovanni G. Martinelli, Carolina C. Terragna, Elena E. Zamagni, Sonia S. Ronconi, Patrizia P. Tosi, Roberto Massimco R M Lemoli, Giuseppe G. Bandini, Maria Rosa M R Motta, Nicoletts N. Testoni, Marilina M. Amabile, Emanuela E. Ottaviani, Nicola Nj Vianelli, Antonio A. De Vivo, Alessandro A. Gozzetti, Santé S. Turamichèle M Cavo

Research output: Contribution to journalArticlepeer-review

Abstract

To assess clinical relevance of minimal residual disease (MRD) in patients withj multiple myeloma (MM), 50 patients were monitored in complete clinical remission (CCR) after autologous or allogeneic stem cell transplantation. Stringent molecular monitoring using clonal markers based upon rearranged! immunoglobulin heavy-chain genes was done in 44/50 MM patients in CCR. Molecular! remission (MCR) was defined as 1 consecutive negative PCR results. 12/44 (27%) molecularly monitored patients achieved MCR; 4/12 turned PCR+ and 1 /4 relapsed. Patients achieving MCR had a significantly lower relapse rate (16% vs. 41% ; I p

Original languageEnglish
JournalBlood
Volume96
Issue number11 PART I
Publication statusPublished - 2000

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Molecular remission after allogeneic or autologou8 transplantation of hematopoietic stem cells for multiple myeloma'. Together they form a unique fingerprint.

Cite this